NEWS

Milan, 8^th September 2023 - Fondazione Gianni Bonadonna and Prada Group, Supporting Partner, in their mutual commitment to promote innovation in clinical research, are pleased to share the results of an important paper, just published in Nature, conducted by Luca Gianni and Giampaolo Bianchini  (Fondazione Michelangelo) and H. Raza Ali  (Cancer Research Institute UK Cambridge). The trial was carried out on 243 patients affected by triple-negative breast cancer, which is an uncommon but particularly aggressive type of breast cancer.

The team of this research found that, depending on specific features in tumors that differ from patient to patient - that is how cells are made and where they are located - it is possible to predict the response to immunotherapy in triple-negative breast tumors.